Gain Therapeutics, Inc.
GANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819411
No open-market purchases or sales by Gain Therapeutics, Inc. insiders were filed in the last 90 days; 50 institutions reported holding it in 13F filings for Q2 2026, worth $17.4M in total; Greenlight Capital is the only superinvestor holding it.
Q1 2024 vs. Q4 2023
How the institutions holding Gain Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 26 | +3 |
| Shares | 1.55M | 588.4K | 1.87M | +910.8K (+95.2%) |
| Value | $5.05M | $1.92M | $7.04M | +$3.92M (+125.3%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Gain Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 566,130 | $2.13M | 0.10% |
| State Street Corp | 30,837 | $116.3K | 0.00% |
| Simplex Trading, LLC | 17,983 | $67.0K | 0.00% |
| Bank of America Corp | 3,375 | $12.7K | 0.00% |
| Citigroup Inc | 684 | $2.58K | 0.00% |
| GWM Advisors LLC | 225 | $848 | 0.00% |
Sold out (3)
Institutions that held Gain Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Dimensional Fund Advisors LP | 15,886 | $51.9K |
| XTX Topco Ltd | 11,453 | $37.4K |
| Advisor Group Holdings, Inc. | 10,000 | $32.6K |
Not filed for Q1 2024 yet (1)
Institutions that held Gain Therapeutics, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Greenlight Capital Inc | 588,410 | $1.92M |